High-tech discovery methods so broadly embraced over the past decade haven't delivered expected gains in productivity. Phenomix Corp. thinks it will fare better by harnessing mouse models of disease, randomly mutagenizing genes, checking the resulting phenotypes for beneficial changes then tracking back to the gene.
1099 North Torrey Pines Road, Suite 160A
La Jolla, CA 92037
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.
Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.
Oral RNA splicing modulator has gone into a Phase II/III trial
The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.
The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.
The country’s life sciences investment head tells Scrip that it is business as usual for the sector despite the rumblings from across the Atlantic.
Wales-based group launches with $140m series A.
